The Journal of
Clinical Psychiatry

Psychopharmacology Schizophrenia/Schizoaffective Disorders

Insights February 17, 2022

Emerging Treatments in Schizophrenia Video

Christoph U. Correll ; Anissa Abi-Dargham ; Oliver Howes

Experts discuss the brain circuits involved in schizophrenia, the current medications, and new agents in phase 3 trials that do not directly block postsynaptic D2 receptors. Phase 2 data on one of these agents, the TAAR1 agonist ulotaront, are summarized.

Read the InfoPack

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD

View current Issue

Related Articles

Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video

Insights

Cognitive Impairment, Reward Pathways and Treatment Challenges in Schizophrenia Video

January 14, 2023

Evaluating different domains of negative symptoms separately to better understand their impact on functional outcomes, particularly cognitive symptoms, is important in the treatment of patients with schizophrenia, especially intervening...

Dawn I. Velligan , Sanjai Rao

Treating Schizophrenia: Side Effects and Adherence Video

Insights

Treating Schizophrenia: Side Effects and Adherence Video

January 14, 2023

One of the central gaps that can affect treatment adherence for individuals with schizophrenia is side effects. Adverse events can lead to substantial impacts across all aspects of daily...

Sanjai Rao

Sequencing Therapy in the Treatment of Schizophrenia Video

Insights

Sequencing Therapy in the Treatment of Schizophrenia Video

January 14, 2023

Balancing and optimizing safety and efficacy when treating patients with schizophrenia can be challenging. New approaches to treatment may impact symptoms more effectively and contribute to better adherence. Sequencing,...

Sanjai Rao